Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 20 May 2026
Revised 29 June 2026
Accepted 21 July 2026

Natural Resources for Human Health 2026, Vol. 6(8s): 1042–1061

KEYWORDS:
patient care, clinical innovation, precision medicine, artificial intelligence, diagnostic medicine, therapeutic advances

Improving Patient Care in Modern Medicine: A Multidisciplinary Review of Diagnostic and Therapeutic Advances, Clinical Innovation, and Artificial Intelligence

Reuben Amala Chandran Manikandan [1], Ibtesam Mazahir [2*], Azhar Rashid [3], Amsa Fatima [4], Fatima Abid [5], Zarnain Ali Shah [6], Muhammad Muneeb [7]

[1]School of Medicine and Dentistry, Queens University Belfast
[2] Faculty of Communication Arts, Chulalongkorn University, Bangkok, Thailand
[2] Mohammad Ali Jinnah University, Karachi
[3] Consultant Oncologist, Department: Clinical and Radiation Oncology, Neurospinal and Cancer Care Institute-NCCI Karachi Pakistan
[4,5,6] University of Lahore
[7] Lecturer, Department of Pharmacy, University of Rasul, Mandi Bahauddin, Punjab, Pakistan 50370
reuben7amala@gmail.com[1], ibtesam.mazahir@gmail.com[2], azhar_rashid@hotmail.com[3], amsa.fatima92@gmail.com[4], Fatima.abid@dnsc.uol.edu.pk[5], zarnain.ali@dnsc.uol.edu.pk[6], muhammad.muneeb@putrasul.edu.pk[7]
*Corresponding Author: Ibtesam Mazahir

ABSTRACT: Modern medicine is being reshaped by advances in diagnostics, therapeutics, precision medicine, digital health, and artificial intelligence (AI). This multidisciplinary review examines how these developments influence patient care across internal medicine, cardiology, neurology, oncology, obstetrics and gynecology, pediatrics, general surgery, orthopedics, emergency medicine, radiology and medical imaging, pathology, pharmacology, and public health. Current evidence indicates that molecular diagnostics, genomic profiling, advanced imaging, biomarkers, minimally invasive procedures, targeted therapies, immunotherapies, pharmacogenomics, remote monitoring, and AI-assisted decision support can improve disease detection, risk stratification, treatment selection, and longitudinal management. AI is particularly relevant to image interpretation, digital pathology, physiological-signal analysis, clinical prediction, drug discovery, and multimodal data integration. However, improved technical performance does not necessarily translate into better clinical outcomes. External validation, calibration, interpretability, representative datasets, workflow integration, patient safety, privacy, regulatory oversight, and equitable access remain essential. Across specialties, the most clinically valuable innovations connect earlier or more accurate diagnosis with an actionable therapeutic pathway and measurable patient benefit. Future progress will depend on multidisciplinary collaboration and on validated technologies that complement rather than replace clinical expertise. A patient-centered framework integrating diagnostic, therapeutic, procedural, pharmacological, public-health, and AI-enabled innovation offers a practical path toward safer, more precise, efficient, and equitable care.

Natural Resources for Human Health
eISSN: 2583-1194

1. INTRODUCTION

Contemporary medicine aims to improve survival, safety, function, quality of life, and the patient experience. Over the past two decades, clinical practice has evolved from predominantly symptom-driven assessment, conventional laboratory testing, and standardized treatment toward a more integrated model incorporating advanced imaging, molecular biomarkers, genomics, minimally invasive interventions, precision pharmacotherapy, digital monitoring, and computational decision support.[1,2]

This shift is particularly important because major diseases rarely remain confined to a single specialty. Patients with diabetes may also have cardiovascular disease, chronic kidney disease, obesity, and neurological complications; patients with cancer may require coordinated input from oncology, surgery, radiology, pathology, genetics, pharmacology, and supportive care; and acutely ill patients may simultaneously require emergency, medical, surgical, imaging, laboratory, and critical-care expertise. Accordingly, the clinical context in which technological innovation must operate is inherently multidisciplinary.[3,4]

Advances in diagnostics have enabled earlier disease detection and more precise characterization of biological heterogeneity. High-resolution computed tomography (CT), magnetic resonance imaging (MRI), positron-emission tomography (PET), advanced ultrasonography, digital pathology, circulating biomarkers, genomic sequencing, and liquid biopsy increasingly augment clinical assessment. Precision diagnostics are most valuable when they change management by identifying a treatable condition, refining prognosis, guiding therapy selection, or preventing unnecessary treatment.[5,6]

Therapeutic innovation has progressed in parallel. Targeted anticancer agents, immune checkpoint inhibitors, newer cardiovascular therapies, genotype-guided treatment, endovascular interventions, robotic surgery, and minimally invasive procedures have broadened treatment options. Precision medicine seeks to match these interventions to individual biological and clinical profiles rather than relying solely on population averages.[1,7]

Artificial intelligence is a cross-cutting component of this transformation. Machine learning, deep learning, natural language processing, computer vision, transformer architectures, and multimodal models can integrate images, physiological signals, laboratory results, clinical notes, and longitudinal electronic health records. Current applications include screening, image interpretation, electrocardiographic analysis, risk prediction, pathology, treatment planning, medication optimization, and population-health surveillance.[8–10]

Discrimination and accuracy alone are insufficient measures of the clinical value of AI. A model that performs well retrospectively may perform poorly in a different hospital, population, device environment, or disease-prevalence setting. Bias, poor calibration, data drift, inadequate external validation, limited interpretability, privacy concerns, automation bias, and workflow incompatibility can reduce benefit or introduce new risks. Meaningful human oversight and clinical validation are therefore essential for safe implementation.[11–13]

This review examines diagnostic, therapeutic, clinical, and AI-enabled innovations across major medical specialties through a single question: how do these innovations improve patient care? Particular emphasis is placed on the relationship between technological performance and clinically meaningful benefit, including earlier diagnosis, safer treatment, improved survival, fewer complications, better function, more appropriate resource use, and improved access.

The distinctive contribution of this review is an outcome-oriented framework that links diagnostic innovation to therapeutic action, multidisciplinary implementation, measurable patient benefit, and the safety and equity requirements of responsible adoption. Artificial intelligence and precision technologies are therefore considered not as endpoints in themselves, but as components of a pathway from technical capability to clinically useful, patient-centered care.

Natural Resources for Human Health
eISSN: 2583-1194



Figure 1. Multidisciplinary model linking diagnostic, therapeutic, clinical, pharmacological, public-health, and AI innovation around patient-centered precision care.

2. REVIEW APPROACH

This article is an evidence-based structured narrative review. Priority was given to peer-reviewed systematic reviews, meta-analyses, randomized controlled trials, major prospective studies, clinical guidelines, and high-quality validation studies addressing contemporary diagnostic and therapeutic modalities. Recent evidence was emphasized, while older landmark studies were retained when they represented major changes in practice or provided essential conceptual background. Because the review spans heterogeneous specialties, interventions, diagnostic methods, and outcomes, the evidence was synthesized narratively rather than statistically pooled.

Evidence is organized along the patient-care pathway: prevention and screening, diagnosis, risk stratification, treatment selection, therapeutic or procedural intervention, monitoring, and long-term management. AI applications are also considered according to evidence maturity, distinguishing proof-of-concept and retrospective performance studies from external validation, prospective evaluation, clinical implementation, and demonstrated patient benefit.



Figure 2. Integrated patient-care pathway from prevention and screening to long-term management.

2.1 Literature Identification and Scope

The literature framework was designed for a structured narrative review rather than a PRISMA systematic review. The core evidence base was identified through PubMed/MEDLINE, supplemented by targeted searches of major journal and guideline-publisher platforms to capture recent specialty guidelines, systematic reviews, meta-analyses, randomized trials, and clinically important validation studies. The principal search period was January 2021 through August 2026, while older landmark studies

were retained when they documented a major change in practice or provided essential conceptual background. A final targeted literature update was performed on 30 August 2026.

Representative search concepts were adapted to each specialty and combined with Boolean operators. Examples included: ("patient care" OR "clinical outcomes") AND ("precision medicine" OR "diagnostic innovation" OR "therapeutic innovation"); ("artificial intelligence" OR "machine learning" OR "deep learning") AND (validation OR implementation OR outcomes); and specialty-specific combinations such as oncology AND ("targeted therapy" OR immunotherapy OR "antibody-drug conjugate" OR "CAR-T" OR "circulating tumor DNA"), radiology AND artificial intelligence AND (prospective OR implementation), and (pharmacogenomics OR "model-informed precision dosing") AND (implementation OR outcomes). Searches focused primarily on English-language human clinical literature. High-quality reviews and guidelines were also examined to identify influential studies not captured by the initial search terms.

Study selection was purposive and evidence-prioritized rather than exhaustive. Titles and abstracts were screened for relevance to diagnosis, treatment, clinical outcomes, implementation, safety, and equity, with full texts considered when necessary to assess clinical relevance. Systematic reviews and meta-analyses were generally preferred for broad statements; contemporary guidelines and randomized or prospective studies were prioritized for therapeutic advances; and independent external or prospective validation studies were prioritized for AI applications. Purely technical reports without a defined clinical use case were not treated as evidence of patient benefit. Consistent with the narrative-review design, formal duplicate screening, study-level risk-of-bias scoring, and PRISMA flow counts were not performed.

2.2 Eligibility and Evidence Prioritization

Evidence directly addressing diagnosis, treatment, clinical outcomes, implementation, or patient safety was prioritized. Systematic reviews and meta-analyses were preferred for broad evidence synthesis, contemporary clinical guidelines and randomized or prospective studies for therapeutic advances, and external or prospective validation studies for AI applications. Purely technical studies without a clear clinical purpose were used cautiously and were not regarded as evidence of patient benefit. Non-human studies, non-clinical engineering reports, unsupported opinion pieces, and duplicate reporting of the same evidence were not used as primary support for clinical conclusions.

Table 1. Search strategy and evidence-prioritization framework

Source/data base	Coverage	Example search concepts	Inclusion	Exclusion	Evidence priority
PubMed/MEDLINE	Jan 2021-Aug 2026; older landmark studies retained	Patient care; precision medicine; diagnostic and therapeutic innovation	Human clinical studies relevant to diagnosis, treatment, outcomes, safety, implementation, or equity	Non-human studies; non-clinical engineering reports; unsupported opinion pieces	Systematic reviews/meta-analyses; randomized/prospective studies; clinical guidelines
Major journal and guideline-publisher platforms	Targeted contemporary update; final search 30 Aug 2026	Specialty-specific terms, including oncology, radiology, pharmacogenomics, AI, and precision dosing	Recent specialty guidelines, major trials, validation studies, and influential reviews	Duplicate evidence; purely technical reports without a defined clinical use case	For AI, independent external or prospective validation prioritized
Reference-list checking of high-quality reviews/guidelines	Supplementary identification of influential studies	Backward identification of landmark and clinically influential evidence	Studies providing essential conceptual background or major changes in practice	Evidence not directly relevant to clinical care or patient outcomes	Higher weight given to evidence closest to demonstrated clinical utility

2.3 Evidence Synthesis

The review encompasses heterogeneous diseases, interventions, technologies, and outcome measures that are not suitable for formal quantitative pooling. Evidence was therefore synthesized within a shared specialty-level framework: diagnostic advances, therapeutic advances, AI or other clinical innovation, demonstrated or plausible patient benefit, and major limitations. For AI, evidence maturity was categorized as technical performance, internal validation, external validation, prospective clinical evaluation, and demonstrated improvement in patient outcomes.

3. DIAGNOSTIC ADVANCES AND PRECISION MEDICINE

Modern diagnostics increasingly combine anatomical, physiological, molecular, and longitudinal information. Genomic sequencing can identify inherited disease mechanisms and clinically actionable variants; molecular profiling can support tumor classification beyond the organ of origin; and biomarkers can contribute to diagnosis, prognosis, and monitoring. Circulating tumor DNA and other liquid-biopsy approaches offer minimally invasive opportunities to characterize disease and detect residual disease, particularly in oncology, although sensitivity, standardization, and clinical applicability remain variable.[5,6]

Advanced imaging has also transformed diagnostic pathways. CT and MRI provide detailed structural information, while functional and molecular imaging characterize physiology and metabolism. Quantitative imaging and radiomics aim to identify reproducible high-dimensional features that complement visual interpretation. Applications in tumor characterization, neurological disease, cardiovascular risk, and treatment-response assessment are promising, but reproducibility across scanners, institutions, and acquisition protocols remains a major requirement.[14,15]

Precision medicine links diagnostic information to therapeutic action. Its value is greatest when a validated biomarker or molecular feature is associated with treatment response, toxicity, or prognosis. The objective is not simply to generate more data, but to identify information that changes a clinical decision and improves an outcome.[1,7]

4. INTERNAL MEDICINE: INTEGRATED MANAGEMENT OF MULTIMORBIDITY

Internal medicine increasingly focuses on multimorbidity rather than on isolated diseases. Many older adults and patients with cardiometabolic disease experience multiple chronic conditions, including hypertension, diabetes, chronic kidney disease, obesity, heart failure, and polypharmacy. Integrated risk assessment, medication reconciliation, renal and hepatic dose adjustment, prevention strategies, and longitudinal monitoring are therefore more important for contemporary care than fragmented disease-specific decisions.[3,16]

Digital health can support this model through home blood-pressure recording, glucose monitoring, wearable physiological sensors, patient portals, and remote follow-up. While these tools can help ensure continuity and offer information between visits to the clinic, their effectiveness depends on patient engagement, the device is reliable, there are appropriate response pathways in place, and the tool is not over-alerting. Decision-support systems are most useful when they prevent avoidable errors or identify deterioration that requires action rather than merely generating additional alerts.[17,18]

In internal medicine, AI can support summarization of complex records, identification of risk patterns, prediction of deterioration, and differential diagnosis. Generalizability is particularly challenging in multimorbidity because real-world patients may differ substantially from selected development cohorts. Clinical judgment remains necessary to balance competing guideline recommendations, treatment burden, frailty, patient goals, and uncertainty.[9,11]

Recent evidence also highlights a practical limitation of digital medicine in multimorbidity: many technologies are designed around individual diseases rather than the cumulative burden of care experienced by patients with multiple chronic conditions. The potential for a patient-care benefit is therefore dependent on the type of digital health technologies: whereas an integrated remote monitoring system could strengthen the continuity of care and create timely awareness and alertness about deterioration, poorly coordinated and fragmented digital systems might lead to treatment burden and disengagement.[59]

5. CARDIOLOGY

Cardiology is an example of the convergence of diagnostics, therapeutics, and digital technologies. Disease detection and phenotyping have advanced by using high sensitivity biomarkers, echocardiography, coronary CT angiography, cardiac MRI, ambulatory rhythm monitoring and wearable devices. In addition to this, there are also highly effective lipid-lowering drugs,

new antiplatelet agents and antithrombotic drugs, evidence-based HF drugs, catheter ablation, PCI and transcatheter structural-heart (TCSH) procedures.[19,20]

In cardiology, AI can support automated ECG interpretation, arrhythmia detection, image segmentation, assessment of ventricular function, and clinical risk prediction. ECG signals are not only used to interpret the heart's normal rhythm but have also been shown to contain information that can be used for the diagnosis of cardiac rhythm disorders and other cardiovascular signals using deep neural networks.[21]

Clinical implementation should focus on clinical utility rather than algorithmic novelty. Misinterpreted rhythm alerts and downstream testing, as well as models with suboptimal predictive capability when applied to different populations or acquisition settings, can add to anxiety and testing. AI-driven cardiovascular care is thus best protected when combined with evidence-based diagnostic pathways and physician oversight.[11,21]

Advances in cardiology are progressing at a faster rate with the use of disease-modifying treatment and less invasive interventions. Today, several complementary drug classes are utilized in the treatment of heart failure such as renin-angiotensin system modulation, evidence-based beta-blockade, mineralocorticoid receptor antagonism, and sodium-glucose cotransporter-2 inhibitors. In addition, the structural-heart programs increasingly use transcatheter approaches for certain cases of valvular disease, and catheter-based rhythm management is evolving. These advances are clinically relevant as they link the precise phenotyping to interventions that reduce hospitalization, symptoms and cardiovascular risk.[19,20]

Going forward, it will likely be important to utilize multiple predictors, including imaging, biomarkers, wearable data and longitudinal data, rather than relying on any single one of these factors. The common denominator is still translation: A highly accurate ECG or imaging algorithm is useful only if it identifies a clinically meaningful state that triggers a clinically useful treatment action and if the algorithm helps to determine the timing or appropriateness of the action.[21,37]

6. NEUROLOGY

Advances in acute stroke treatment, neuroimaging, molecular diagnosis, and disease-specific therapies have substantially improved neurological care. Mechanical thrombectomy substantially changed acute stroke care for selected patients with LVO and the potential to achieve effective reperfusion outside of the traditional time window in the appropriate patient.[22,23]

The use of MRI, CT angiography, perfusion imaging, electroencephalography, molecular and genetic testing is increasingly supplementing clinical diagnosis and guiding treatment decisions in stroke, epilepsy, neurodegenerative disease, demyelinating disorders, and neuromuscular disease. Although AI can help with detection, segmentation, analysis of seizures, and prognosis, there are significant challenges with neurological heterogeneity and clinically important rare presentations that mandate external validation.[8,14]

The principal goals of innovation in neurology are to reduce time to treatment, detect reversible disease, enhance functional outcome, and assist long-term disease management. Automation should be part of clinically supervised pathways due to the significant disability caused by small diagnostic errors.

Therapeutic innovation in neurological disorders extends beyond reperfusion therapy. There are new disease-modifying strategies in neuroimmunology, inherited neurological disease, and neurodegeneration such as the use of monoclonals, antisense, and gene-directed therapy in specific diseases. Anti-amyloid monoclonal antibodies have shifted the treatment landscape of Alzheimer disease toward a biologically targeted approach for selected patients and have introduced new challenges for biomarker confirmation, MRI monitoring for treatment-emerging imaging abnormalities, and more.[38,39]

The developments above highlight the importance of multidisciplinary neurological care. Advanced therapy may involve collaboration between neurologists, neuroradiologists, geneticists, pharmacists, infusion, rehabilitation, and primary care. The patient care benefit, therefore, depends on the selection, monitoring and management of potential complications as well as on the realistic assessment of the functional outcomes of the drug or procedure.[38]

7. ONCOLOGY

Oncology is one of the clearest applications of precision medicine. Immunohistochemistry, genomic profiling, molecular classification and liquid biopsy are being more commonly used to supplement histopathology. These tools can detect actionable changes, pinpoint prognosis, and inform specific treatments. Molecularly targeted agents, 'checkpoint inhibitors' of the immune

system, antibody-drug conjugates, cellular therapies, advanced radiotherapy and increasingly personalized combinations are all included in therapeutic progress.[5–7]

Immune checkpoint blockade has led to sustained responses in subgroups of patients across various malignancies, and has positioned immunotherapy as a key therapeutic platform. Predictive biomarkers and multidisciplinary management are needed however, because benefit is variable and can be accompanied by immune-related toxicity.[24]

In oncology, AI applications have expanded rapidly across radiology, pathology, genomics, and outcome prediction. Computational pathology can classify tissue patterns and quantify features that may be difficult to assess reproducibly by visual inspection alone. Eventually, multimodal systems could integrate these four elements, as well as other clinical variables, to assist in therapeutic decision-making. Translation must be validated against clinically relevant endpoints and a variety of populations, and this must be transparent.[10,15]

The organization of therapeutic oncology becomes more and more biomarker-driven. Genomic and protein biomarkers identify patients most likely to respond to targeted agents in precision molecular therapy, and immune-checkpoint inhibition has revolutionized the treatment of many malignancies. The modern antibody-drug conjugates (ADCs) take the targeted approach further, by fusing an antibody with a cytotoxic agent; but therapeutic resistance, tumor heterogeneity, and pharmacological side effects are still significant barriers.[53]

Another therapeutic platform is cellular therapy. CAR-T therapy has proven to provide significant benefit in certain B-cell malignancies and multiple myeloma, however efficacy in most solid tumors is still under investigation due to antigen heterogeneity, impaired trafficking, and the immunosuppressive tumor microenvironment.[54] This is an important distinction: established benefit in hematological malignancy must not be extended to solid tumors without specific evidence of benefit.

The molecular characterization of circulating tumor DNA is also shifting to measurable residual disease and treatment-guidance research. In some solid tumors, the detection of ctDNA following apparently curative therapies is a strong predictor of survival or quality of life and may anticipate tumor recurrence seen on imaging, but targeting treatment based on the presence or absence of ctDNA should be considered an emerging treatment strategy until prospective interventional studies have shown that molecular residual disease-based treatment changes produce a survival or quality of life benefit.[55]

A major challenge in precision oncology is that new biomarkers and therapies may change management before their effectiveness has been established in representative populations. How increasingly complex treatment platforms relate to benefit at the population level will be evaluated in pragmatic trials, real-world evidence, resistance monitoring, toxicity management, affordability and access to molecular testing.

8. OBSTETRICS AND GYNECOLOGY

Obstetrics and gynecology encompasses preventive medicine, imaging, surgery, oncology, reproductive medicine and monitoring of the mother and fetus. Enhanced opportunities for earlier diagnosis and individualized management have arisen with advances in prenatal screening, ultrasonography, noninvasive prenatal testing, and minimally invasive gynecological surgery, assisted reproduction, as well as risk-based maternal care approaches.[25]

Some examples of AI applications are fetal imaging assistance, cardiotocography analysis, prediction of obstetric complications, gynecological image classification, and clinical decision support. These types of applications require special attention in evaluation because the potential for errors in the patient and fetus, and high variation in prevalence and care pathways among populations and health systems. Rather than accuracy, safety, calibration, fairness, and clinical consequences should be considered when evaluating the performance.[12,13]

Innovation in this area should maintain informed consent, autonomy of reproduction, privacy and shared decision-making with the patient. The most effective use of technology is in terms of timely detection of high-risk pregnancy, proper referral, safer treatment procedure and equitable access to maternal and reproductive healthcare.

New solutions in obstetrics and gynecology also encompass fertility preserving surgery, new assisted reproductive techniques, gynecological cancer targeted treatment and the growing use of personalized strategies for endometriosis, abnormal uterine bleeding and menopausal care. The reduction in recovery burden associated with minimally invasive and robotic procedures may be modest for some procedures, depending on the indication, surgeon experience, and when compared with high-quality conventional laparoscopy.[40]

9. PEDIATRICS

In pediatric medicine, physiology, pharmacology, development, and disease must be interpreted in an age-specific context. There is a special role for genomic sequencing in the investigation of children with suspected rare or inherited disorders, as it can terminate diagnostic odysseys and in some cases guide treatment for a specific disease.[26]

Use of digital monitoring and AI could aid in the early warning system, congenital disease detection, pediatric imaging, and individualized risk assessment. But a model trained primarily from adult data should not be considered to be safe for children. Pediatric specific validation is needed due to developmental changes, small sample sizes, rare diseases, weight based dosing and ethical concerns of consent and data use.[11,26]

Targeted and gene-based therapies are increasingly available for certain disorders in pediatrics. The principle that extends beyond this is that innovation should benefit neurodevelopment, long term function, family burden, transition to adult care, as well as survival.

Cell and gene therapies for specific inherited (certain), hematological, oncological and neuromuscular disorders are driving the growth of pediatric precision therapeutics. These treatments can be life-changing, but present unique questions about the long-term safety, manufacturing, delivery, cost, and availability of these treatments. In recent years, there has been a focus in pediatric literature on clinical progress, as well as the need for delivery models that can be used to make these therapies available outside of limited, highly specialized centers.[41]

The innovation process for children needs to be life-course oriented. Developmental stage, future fertility, neurocognitive development, caregiver burden, long-term toxicities, and transition to adult services should all be taken into consideration when making treatment decisions. The most powerful of the pediatric technologies are those that have been validated specifically in children and those related to outcomes that are relevant to children and families and not derived from adult performance.[41,42]

10. GENERAL SURGERY

General surgery has increasingly adopted minimally invasive and image-guided approaches, where appropriate, to reduce tissue injury and accelerate recovery. New technologies include laparoscopy, the use of robots, faster perioperative pathways, newer energy devices, improved fluorescence, and better monitoring of the perioperative period to broaden the range of possibilities.[27]

Enhanced Recovery After Surgery (ERAS) programs demonstrate that innovations are not just limited to devices. It is possible to recover better and avoid unnecessary variations by providing standardized pathways, combining the elements of anesthesia, analgesia, nutrition, mobilization, fluid management and surgical technique based on evidence. This systems approach is especially applicable to contemporary patient care as the outcome is the result of more than just the operation, it reflects the entire perioperative system.[27]

AI-aided surgical planning, anatomical recognition, real-time guidance, workflow analysis, and postoperative risk assessments are emerging as key areas in the field of AI-assisted surgery. Prior to the introduction of autonomous or semi-autonomous functions, systems must be well tested for safety, have clear accountability and evidence that support yields clinically meaningful results.[13]

11. ORTHOPEDICS

The field of orthopedic innovation is also seeing advances in cross-sectional imaging, computer-assisted navigation, robotic arthroplasty, patient-specific planning, modern implant design, biologic approaches to orthopedic surgery, and enhanced rehabilitation. These technologies aim to improve procedural accuracy, implant positioning, mobility, pain, and functional recovery.

AI is currently being evaluated for fracture detection, osteoarthritis grading, implant assessment, surgical planning and prediction of postoperative outcomes. Image-based interpretation is technically well suited to AI due to the standardization and availability of radiographs, but requires attention to subtle fractures, uncommon implants, pediatric anatomy and differences in acquisition in order to be clinically useful. The key question is whether AI improves diagnostic accuracy, reduces time to treatment, or improves functional outcomes.[8,14]

Recent studies on robotic-assisted arthroplasty provide an example of the distinction between precision and benefit for the patient. New systematic reviews and randomized-trial meta-analyses show benefits for selected alignment or radiographic

outcomes with robotic TKA, and variable results in functional outcomes, complications, operative time and cost. The potential for improvement in component positioning and selected technical outcomes is similar to robotic THA, but outcomes are dependent on system, surgeon experience, and length of follow-up.[43–45]

Therefore, the innovation in orthopedics should be judged not only based on the implant position, but also on the outcomes. Whether technological precision leads to better care is determined by the extent to which it results in pain, mobility, return to activity, revision, complications, burden of rehabilitation, and cost-effectiveness. Like imaging applications in other specialties, AI technology for fracture detection and outcome prediction must be validated with external data.[43–45]

12. EMERGENCY MEDICINE

Emergency medicine requires rapid decisions under conditions of uncertainty. Point-of-care ultrasonography, high-sensitivity biomarkers, rapid CT, bedside testing, structured trauma systems, stroke pathways, and sepsis protocols have helped to expedite the recognition and treatment of life-threatening conditions. Turnaround time and intervention is highly related to the value of diagnostic innovation in this setting.[28]

Predictive models can be used to aid in triage, detecting deterioration, identifying signs of sepsis, prioritizing imaging, and disposition. However, emergency populations are diverse and the prevalence of disease fluctuates by place and time. If the system is not appropriately calibrated, it can produce too many false alarms or not react to unusual displays. It is therefore critical to conduct prospective evaluation in the proposed workflow.[11,29]

Human factors play a more crucial role in the context of emergency AI. Clinicians require outputs that are timely, interpretable and usable for action, and are not a burden on clinical assessment. Decision support should be such as to lower the cognitive load, not create more information to deal with. Emergency-medicine AI is being explored in the areas of triage, diagnosis, prediction, disposition, and operational decision-making, as evidenced by recent systematic reviews. Triage applications are especially appealing as they can benefit those who are at risk of deterioration, but both false reassurance and unnecessary escalation can cause harm. Prospective evaluation should therefore assess discrimination, not only time to treatment, but also the risk of a missed critical illness as well as resource use and unintended consequences.[46,47]

13. RADIOLOGY AND MEDICAL IMAGING

Radiology is one of the most established clinical domains for medical AI because it generates large volumes of digital data and includes many tasks that can be formulated as detection, classification, segmentation, or quantification. Deep learning has been shown to perform well in some imaging applications, and can help with prioritization, measurement, lesion detection and workflow management.[8,14]

However, the job of the radiologist does not stop there. Clinical context, comparison to previous studies, incidental findings, protocol selection, uncertainty, communication and integration of multiple modalities remain critical. AI should thus be considered as an augmentative tool that can help automate repetitive measurements or identify abnormalities that the clinician will still need to provide a context for.[12,14]

A major issue is generalizability. Scanner manufacturer, protocol, institution, population, disease spectrum or image quality may influence performance. Claims of routine clinical readiness should follow, rather than precede, adequate external and prospective validation; and post-deployment monitoring should be done to identify the performance drift.[11,12]

Although the literature on the implementation of algorithms in radiology has been published in the last few years, the focus has been on the algorithm's accuracy in isolation rather than the clinical system within which the algorithm is used. When AI alters screening, prioritization or reporting, a clearly defined clinical problem, representative local data, stakeholder buy-in, software integration, governance, and user-centered evaluation in intended workflow are important factors in successful implementation; the latter includes outcomes that involve more than just image level discrimination, such as recall, diagnostic delay, workload, downstream testing and patient outcomes.[56,61]

14. PATHOLOGY AND LABORATORY MEDICINE

Pathology is increasingly integrating conventional microscopy with digital and computational approaches based on whole-slide imaging. This technique allows for remote diagnosis, quantification, archiving, teaching, and assisted identification using

artificial intelligence. Molecular pathology provides information on a genomic, transcriptomic, and protein level that may help classify the disease and choose therapy.[10,15]

Computational pathology may aid in tumor localization, grading, segmentation, biomarker quantification, and perhaps prognosis. The most significant benefit of computational pathology in the future will come from the combination of morphological analysis with molecular and clinical data rather than image analysis alone. It may connect morphology and therapy selection.[10]

Automated processes, advanced biomarkers, and decision support are also available for laboratory medicine. However, the importance of preanalytical error, variability, reference intervals, and context remains crucial. Interpretation by computer cannot replace the reliable source data.

A 2024 systematic review and meta-analysis of AI applications to whole-slide pathology images reported good performance in diagnosing various diseases. But there were also serious problems with the quality of studies and their applicability. Most articles included had high or unclear risk of bias or applicability domains, thus emphasizing the difference between promising retrospective performance and sufficient evidence for clinical use.[48]

Another relevant topic is the difference between regulatory availability and clinical evidence. In 2024, digital pathology AI products were analyzed in terms of the availability of peer-reviewed independent clinical validation.[49]

15. PHARMACOLOGY AND PERSONALIZED MEDICINE

Pharmacological practice increasingly depends on pharmacogenomics, therapeutic drug monitoring, model-informed precision dosing, and safety monitoring of real-world use. There may be genetic factors that affect metabolism, transport, pharmacodynamics, and adverse effects of medications. Personalized treatment can be guided by genotype in case of sufficient gene-drug evidence.[30]

Machine-learning algorithms may integrate genomic, laboratory, physiological, medication, and longitudinal data to predict patient-specific treatment response or adverse events. This approach is most relevant in situations with narrow therapeutic windows and large variability in response. Nevertheless, personalized dosing should be prospectively validated due to the risks of overtreatment or under-dosage that directly cause harm.[30,31]

Medication safety also depends on systems-oriented practices such as medication reconciliation, interaction checks, renal/hepatic dose adjustments, antimicrobial stewardship and deprescribing. Thus, precision pharmacology should complement rather than substitute existing evidence-based guidelines on safe prescribing.

Precision dosing literature of recent years provides examples of the possibility and lack of evidence needed. Model-informed precision dosing combines population pharmacokinetics, patient characteristics, drug concentrations, biomarkers and clinical evolution of the situation in order to personalize drug therapy, especially in cases of narrow therapeutic index drugs. A 2024 state-of-the-art review concluded that these methods are becoming increasingly technically mature but still need randomized and prospective evidence that proves their contribution to patient outcomes.[57,60] Pharmacogenomics implementation faces a similar translational challenge: validated gene-drug relationships can provide a basis for safer prescribing but their clinical utility depends on guideline-validated interpretation of results, timely testing, clinical decision support, physician training and access equity.[58]

16. PUBLIC HEALTH AND EPIDEMIOLOGY

Modern healthcare depends on systems operating on the population level that affect prevention, surveillance, access to care and resource allocation. EHRs, registries, geospatial data, genomic surveillance and digital reporting can support epidemiology and early detection of new threats. Predictive analytics can assist in identifying populations with higher risk and in organizing preventive measures among them.[32]

Usage of AI in public health raises concerns about equity. Datasets of healthcare have inherent bias since they represent current patterns of access, testing, diagnostics and reporting. AI models trained on them will replicate these structural inequities if social and demographic biases are not considered. Evaluation of fairness, open governance, community involvement and representative datasets are thus vital.[13,33]

Public-health innovation should be judged not only by predictive performance but also by whether it improves vaccination, testing, prevention, outbreak response, resource allocation, and access to care. Innovations that can function only in high-resource settings will likely increase rather than decrease health disparities.[62]

Table 2. Multidisciplinary advances and implications for patient care

Specialty	Representative advances	Potential patient-care contribution
Internal medicine	Remote monitoring, integrated risk assessment, clinical decision support	Continuity of care; safer multimorbidity management
Cardiology	Advanced imaging, wearables, transcatheter therapy, AI-ECG	Earlier detection; risk stratification; less invasive treatment
Neurology	Advanced neuroimaging, thrombectomy, genomic diagnostics	Faster treatment; improved functional outcomes
Oncology	Molecular profiling, liquid biopsy, immunotherapy, targeted therapy	Therapy selection; response monitoring; personalized care
Obstetrics & gynecology	Prenatal screening, advanced ultrasound, minimally invasive surgery	Earlier risk recognition; safer maternal and reproductive care
Pediatrics	Genomic diagnosis, age-specific decision support	Earlier rare-disease diagnosis; individualized management
General surgery	Laparoscopy, robotics, ERAS, image guidance	Reduced procedural burden; faster recovery
Orthopedics	Navigation, robotics, advanced imaging, rehabilitation analytics	Procedural precision; functional recovery
Emergency medicine	Point-of-care testing, rapid imaging, predictive triage	Shorter time to diagnosis and intervention
Radiology	Quantitative imaging, deep learning, workflow prioritization	Detection assistance; measurement; efficiency
Pathology	Digital pathology, molecular profiling, computational pathology	More precise classification and biomarker assessment
Pharmacology	Pharmacogenomics, precision dosing, safety analytics	Safer and more individualized medication use
Public health	Digital surveillance, predictive epidemiology, geospatial analytics	Prevention; surveillance; resource allocation

16.1 Therapeutic Innovation in Modern Medicine

Therapeutic innovation now extends beyond molecularly targeted drugs to include the use of less invasive procedural intervention, disease-modifying therapy, biologics, precision dosing, cell and gene therapy, and immunotherapy. All these advances have a common goal: to go beyond the standard approach of a uniform treatment, to one based on disease mechanism, patient phenotype, predicted response and treatment risk. Their clinical significance is greatest if a diagnostic or prognostic marker provides a clinically relevant pathway and if comparative evidence shows a benefit over a known benchmark treatment.

The quality of clinical evidence supporting therapeutic claims is variable in oncology, neurology, cardiology, pediatrics, surgery and pharmacology. Some innovations have demonstrated improvements in survival, hospitalization, symptoms, or functional outcomes in randomized trials and have entered clinical guidelines; others improve procedural precision or biomarker measurement without yet establishing superior patient-centered outcomes. The manuscript thus differentiates demonstrated

benefits from potential benefits and does not equate technical novelty, regulatory availability or reasonable scientific plausibility with clinical effectiveness.

The combination of accurate diagnosis, adaptive therapy, longitudinal monitoring, and multidisciplinary delivery will be increasingly relied upon for future therapeutic advances. Implementation issues that are important include durability of benefit, long-term toxicity, resistance, treatment burden, affordability, health-system capacity, and equitable access. Crucially, these factors are relevant for high-cost cell and gene therapies, complex biologics, robotic procedures and precision-dosing platforms, which require special infrastructure.

17. AI ACROSS THE CLINICAL PATHWAY

Table 3. Artificial intelligence across the patient-care pathway

Care stage	AI-supported functions	Key clinical requirement	Representative applications
Screening	Pattern detection, risk estimation, population stratification	High sensitivity with appropriate specificity and equity	Population screening; oncology risk
Diagnosis	Image/signal interpretation, multimodal classification	External validation and clinician oversight	Radiology; pathology; cardiology
Risk stratification	Prediction of deterioration, complications, recurrence	Calibration and actionable thresholds	Emergency medicine; internal medicine; cardiology
Treatment selection	Response prediction, molecular matching, decision support	Prospective evidence of clinical utility	Oncology; pharmacology; precision medicine
Procedures	Planning, navigation, workflow recognition	Safety testing and clear accountability	Surgery; orthopedics; interventional care
Medication management	Dose optimization, interaction/toxicity prediction	Reliable data and prospective validation	Pharmacology; antimicrobial stewardship
Monitoring	Wearable analytics, remote deterioration detection	Low false-alert burden and response pathway	Cardiology; chronic disease; pediatrics
Public health	Surveillance, forecasting, resource prioritization	Representative data, governance, fairness	Epidemiology; outbreak surveillance

Large language models and foundation models offer opportunities for clinical summarization, question answering, documentation support, and multimodal reasoning. However, they also introduce risks including hallucinated or factually fabricated content, reasoning errors, incomplete or inaccurate attribution, privacy concerns, automation bias, and over-reliance on generated outputs. Retrieval and grounding can reduce some errors but do not eliminate them.[34,35]

Explainability is clinically useful when it helps users understand the basis of a recommendation, recognize uncertainty or failure, and appropriately challenge an output. By contrast, post hoc rationalizations may be misleading. Contemporary reporting and governance frameworks can strengthen responsible evaluation. TRIPOD+AI provides updated reporting guidance for clinical prediction-model studies using regression or machine-learning methods, emphasizing transparent methods, evaluation, fairness, and reproducibility.[50]

FUTURE-AI extends the focus across the AI lifecycle through principles of fairness, universality, traceability, usability, robustness, and explainability, including development, validation, deployment, and monitoring.[51] For large language models, TRIPOD-LLM adds task-specific reporting requirements, human oversight, and transparent evaluation.[52] These frameworks

do not prove clinical effectiveness, but they improve the conditions under which evidence can be interpreted and systems can be governed responsibly.

The most defensible model for clinical AI is augmentation rather than replacement. Algorithms can rapidly analyze high-dimensional data, whereas clinicians contribute contextual reasoning, physical examination, ethical judgment, communication, and professional accountability. When more than one medically reasonable treatment option exists, patient preferences and values remain central to decision-making.

18. FROM TECHNOLOGICAL PERFORMANCE TO CLINICAL BENEFIT

Medical innovation is often assumed to improve care when it improves a technical metric. Measures such as diagnostic accuracy, area under the receiver operating characteristic curve, segmentation quality, and prediction error are important, but they are intermediate endpoints. Clinical usefulness requires reliable performance in external datasets, meaningful influence on clinical decisions, feasible integration into real-world workflows, and, most importantly, patient benefit that outweighs potential harm.[11,12,48,49]

The evidentiary pathway can therefore be viewed as a progression from technical performance to internal validation, independent external validation, prospective clinical evaluation, workflow integration, and ultimately demonstrated patient benefit. Failure at any stage may limit adoption. External validation assesses transportability, prospective studies evaluate workflow and human factors, and outcome studies determine whether changes in diagnosis or decision-making translate into better patient outcomes.[11,12]



Figure 3. Evidence-maturity pathway from technical performance through validation, prospective evaluation, workflow integration, demonstrated patient-outcome benefit, and post-deployment monitoring.

Table 4. Evidence maturity of representative multidisciplinary innovations

Specialty	Innovation	Evidence type	Patient benefit	Main limitation	Evidence maturity
Cardiology	Guideline-directed heart-failure pharmacotherapy	Randomized trials / guidelines	Demonstrated reductions in hospitalization and cardiovascular risk	Implementation and treatment tolerance	High
Neurology	Mechanical thrombectomy for selected large-vessel stroke	Randomized trials / meta-analysis	Demonstrated functional-outcome benefit	Time, imaging selection, system capacity	High
Oncology	Checkpoint inhibition in biomarker-appropriate cancers	Randomized trials / guidelines	Demonstrated survival benefit in selected malignancies	Primary/acquired resistance and toxicity	High

Specialty	Innovation	Evidence type	Patient benefit	Main limitation	Evidence maturity
Oncology	ctDNA-guided treatment after curative-intent therapy	Prognostic cohorts / emerging interventional trials	Potential to identify molecular residual disease earlier	Clinical utility of treatment change not yet established	Emerging
Orthopedics	Robotic arthroplasty	Systematic reviews / randomized trials	Demonstrated technical precision; patient-reported superiority variable	Cost, operative time, uncertain incremental functional benefit	Moderate
Radiology	AI-assisted image interpretation	Retrospective/external validation; growing prospective evidence	Potential efficiency and detection benefit; outcome benefit task-specific	Dataset shift, workflow effects, downstream testing	Moderate / task-dependent
Pharmacology	Model-informed precision dosing	Reviews / implementation studies	Potentially improves target exposure and reduces toxicity	Limited prospective outcome trials for many drugs	Emerging to moderate
Pediatrics	Selected cell and gene therapies	Trials / regulatory and specialty evidence	Transformative benefit in selected inherited/hematologic disorders	Long-term safety, cost, specialized access	High for selected indications
Public health	AI-enabled surveillance	Observational / implementation evidence	Potential earlier detection and resource prioritization	Governance, bias, privacy, actionability	Emerging

19. MULTIDISCIPLINARY INTEGRATION AND PATIENT-CENTERED OUTCOMES

The clinical value of innovation depends on its connection to diagnosis, treatment, and meaningful outcomes. A molecular test has limited value if it does not alter management; an imaging algorithm has limited value if its output is not followed by appropriate and timely action; and a predictive model has limited value if clinicians cannot use its output to guide care. Modern care should therefore be designed as an integrated process rather than as a collection of isolated technologies.

Multidisciplinary teams are particularly important in complex cancer, cardiovascular disease, neurological disease, high-risk pregnancy, trauma, and multimorbidity. Shared decision-making can integrate specialist expertise and reduce conflicting or redundant care. Technology cannot replace clear clinical accountability and communication.[4]

The ultimate objective is improvement in patient-centered outcomes, including mortality, complications, functional status, quality of life, symptom burden, diagnostic delay, adverse drug reactions, hospitalization, treatment adherence, and access to care. Studies reporting technical accuracy alone should be interpreted as evidence of performance rather than evidence of improved care.[11,12]

20. SAFETY, ETHICS, EQUITY, AND REGULATION

Table 5. Major barriers and practical safeguards

Barrier	Potential consequence	Safeguard
Dataset bias	Unequal performance across groups	Representative datasets and subgroup validation
Poor external validity	Failure in new institutions or populations	Independent multicenter validation
Weak calibration	Misleading absolute risk estimates	Calibration assessment and local recalibration
Limited interpretability	Inappropriate trust or rejection	Transparent interfaces, uncertainty, auditability
Workflow mismatch	Low adoption or alert fatigue	Human-centered implementation testing
Privacy/security risk	Loss of confidentiality or system compromise	Governance, access control, cybersecurity
Automation bias	Overreliance on algorithmic output	Training and mandatory clinical oversight
Digital inequality	Widening health disparities	Accessible design and equitable deployment
Regulatory uncertainty	Unsafe or inconsistent implementation	Risk-based evaluation and post-deployment monitoring

Bias is a critical concern in AI. Unequal performance may arise from underrepresentation by sex, age, ancestry, socioeconomic status, disease severity, or type of health-care setting. Overall accuracy does not establish fairness; performance should be assessed across relevant subgroups and externally validated. Infrastructure, digital literacy, affordability, accessibility, and the availability of clinicians who can act on technological findings are also central to equity.[13,33]

Privacy and governance are equally important because data-intensive systems rely on large volumes of health information. Appropriate consent, de-identification, data security, access control, data minimization, and transparent governance should accompany their use. Federated learning and other privacy-preserving approaches can reduce the need to centralize data, but they do not remove requirements for governance, validation, and security.[36]

Regulatory evaluation should be proportionate to clinical risk. Systems that influence diagnosis or treatment require evidence appropriate to their intended use, clear documentation of performance, controlled update procedures, and post-deployment surveillance. Continuously learning systems require particular attention because model behavior may change after initial validation.[12]

21. OBSTACLES TO IMPLEMENTATION

Several implementation barriers recur across specialties. Evidence may be technically promising but clinically immature; interoperability among electronic health records, imaging systems, laboratories, devices, and genomic platforms remains limited; poorly designed interfaces can contribute to alert fatigue; implementation requires training, maintenance, cybersecurity, and governance in addition to software procurement; and unequal technological infrastructure may restrict adoption in resource-limited settings.



Figure 4. Principal barriers and safeguards for safe and equitable clinical implementation.

A further challenge is the tendency to equate innovation with benefit. New technologies should be compared with current standards of care, including simpler alternatives when appropriate. Cost-effectiveness, opportunity costs, and testing burden are therefore important considerations. A technology that modestly improves a surrogate endpoint while substantially increasing complexity or cost may not improve patient care.

21.1 Strengths and Limitations of This Review

A major strength of this review is its multidisciplinary synthesis of diagnostic, therapeutic, procedural, pharmacological, public-health, and AI-enabled innovations within a single patient-care framework. It consistently distinguishes technical performance from clinical usefulness and emphasizes the link among an innovation, the decision it influences, and the outcome that matters to the patient. By considering established therapies alongside emerging technologies, the review also permits comparison of evidence maturity across specialties.

This review also has important limitations. It is a structured narrative review rather than a systematic review; study identification was evidence-driven and was not intended to capture every eligible publication, and duplicate screening and formal study-level risk-of-bias assessment were not performed across specialties. Heterogeneity in study design, populations, interventions, and outcomes precluded quantitative pooling. Rapidly evolving areas, including AI, cell and gene therapy, precision oncology, and digital health, may also change after the final literature update. The conclusions should therefore be interpreted as a clinically focused synthesis of selected high-quality evidence rather than an exhaustive estimate of the effect of every technology.

22. FUTURE DIRECTIONS

Future medicine is likely to become increasingly multimodal, longitudinal, and personalized. Integrating genomics, imaging, pathology, laboratory findings, physiological measurements, medication data, social determinants, and patient-reported outcomes may provide a more comprehensive representation of health and disease. Multimodal AI may facilitate this integration, but clinically useful systems must demonstrate robustness across institutions and populations.[9,10]

Prospective trials and implementation studies should increasingly determine whether AI-assisted care improves outcomes compared with usual care. Reporting should include calibration, subgroup-specific performance, external validation, workflow effects, safety events, and resource utilization. Transparent reporting standards can improve reproducibility and help clinicians distinguish promising research systems from tools ready for clinical use.[11,12]

Precision medicine will continue to advance as molecular classifications become more clinically actionable. Pharmacogenomics, targeted therapy, immunotherapy, and individualized dosing may increasingly connect biological variation with treatment decisions. A central challenge will be extending access beyond highly specialized centers while avoiding wider global disparities.[7,30]

Human-centered design should remain a core principle. The objective is not maximal automation but better care. Systems should present information at the appropriate time and in the appropriate context, communicate uncertainty, allow clinicians to question or override outputs, respect patient autonomy, and support the therapeutic relationship.[13]

23. CONCLUSION

Four conclusions emerge from this multidisciplinary review. First, precision diagnostics are most valuable when imaging, biomarkers, genomics, and pathology inform an actionable treatment decision rather than functioning as isolated tests.

Second, the greatest clinical value arises from innovations that cross specialty boundaries and span the full patient-care continuum. Diagnosis, therapy, procedures, pharmacology, monitoring, and public-health systems are most effective when coordinated as components of integrated care delivery.

Third, artificial intelligence is most appropriately used as an assistive technology. Its strongest role is to help clinicians interpret complex information, identify clinically important risk, automate repetitive tasks, and improve consistency while preserving the human contribution to contextual reasoning, communication, ethics, and shared decision-making.

Fourth, a major remaining gap is prospective, outcome-based validation. Accuracy and retrospective performance alone are insufficient. Next-generation innovations should demonstrate external validity, safe workflow integration, equitable performance, and measurable improvement in patient outcomes. The principal contribution of this review is therefore its outcome-oriented framework linking diagnostic innovation to therapeutic action, multidisciplinary implementation, patient benefit, and the safety and equity conditions required for responsible adoption. Priority research areas include prospective comparative trials, independent external validation, health-economic evaluation, subgroup and equity assessment, implementation science, and post-deployment surveillance.

REFERENCES

[1] Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793-795. doi:10.1056/NEJMp1500523.

[2] Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17:507-522. doi:10.1038/nrg.2016.86.

[3] Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37-43. doi:10.1016/S0140-6736(12)60240-2.

[4] Taberna M, Gil Moncayo F, Jané-Salas E, et al. The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020;10:85. doi:10.3389/fonc.2020.00085.

[5] Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223-238. doi:10.1038/nrc.2017.7.

[6] Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20:71-88. doi:10.1038/s41576-018-0071-5.

[7] Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372:2229-2234. doi:10.1056/NEJMsb1503104.

[8] Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44-56. doi:10.1038/s41591-018-0300-7.

[9] Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380:1347-1358. doi:10.1056/NEJMra1814259.

[10] Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. J Intern Med. 2020;288:62-81. doi:10.1111/joim.13030.

[11] Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17:195. doi:10.1186/s12916-019-1426-2.

[12] Wiens J, Saria S, Sendak M, et al. Do no harm: a roadmap for responsible machine learning for health care. Nat Med. 2019;25:1337-1340. doi:10.1038/s41591-019-0548-6.
[13] World Health Organization. Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. Geneva: WHO; 2021.
[14] Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60-88. doi:10.1016/j.media.2017.07.005.
[15] Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441-446. doi:10.1016/j.ejca.2011.11.036.
[16] Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition—multimorbidity. JAMA. 2012;307:2493-2494. doi:10.1001/jama.2012.5265.
[17] Steinhubl SR, Muse ED, Topol EJ. The emerging field of mobile health. Sci Transl Med. 2015;7:283rv3. doi:10.1126/scitranslmed.aaa3487.
[18] Keesara S, Jonas A, Schulman K. COVID-19 and health care's digital revolution. N Engl J Med. 2020;382:e82. doi:10.1056/NEJMp2005835.
[19] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726. doi:10.1093/eurheartj/ehab368.
[20] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Circulation. 2021;143:e72-e227. doi:10.1161/CIR.0000000000000923.
[21] Hannun AY, Rajpurkar P, Haghpanahi M, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69. doi:10.1038/s41591-018-0268-3.
[22] Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387:1723-1731. doi:10.1016/S0140-6736(16)00163-X.
[23] Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378:11-21. doi:10.1056/NEJMoa1706442.
[24] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350-1355. doi:10.1126/science.aar4060.
[25] American College of Obstetricians and Gynecologists. Screening for fetal chromosomal abnormalities: ACOG Practice Bulletin No. 226. Obstet Gynecol. 2020;136:e48-e69. doi:10.1097/AOG.0000000000004084.
[26] Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med. 2018;3:16. doi:10.1038/s41525-018-0053-8.
[27] Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: a review. JAMA Surg. 2017;152:292-298. doi:10.1001/jamasurg.2016.4952.
[28] Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392(10141):75-87. doi:10.1016/S0140-6736(18)30696-2.
[29] Wong A, Otles E, Donnelly JP, et al. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med. 2021;181:1065-1070. doi:10.1001/jamainternmed.2021.2626.
[30] Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343-350. doi:10.1038/nature15817.
[31] Darwich AS, Ogungbenro K, Vinks AA, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646-656. doi:10.1002/cpt.659.
[32] Salathé M. Digital epidemiology: what is it, and where is it going? Life Sci Soc Policy. 2018;14:1. doi:10.1186/s40504-017-0065-7.
[33] Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366:447-453. doi:10.1126/science.aax2342.
[34] Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620:172-180. doi:10.1038/s41586-023-06291-2.
[35] Lee P, Bubeck S, Petro J. Benefits, limits, and risks of GPT-4 as an AI chatbot for medicine. N Engl J Med. 2023;388:1233-1239. doi:10.1056/NEJMsr2214184.

[36] Rieke N, Hancox J, Li W, et al. The future of digital health with federated learning. NPJ Digit Med. 2020;3:119. doi:10.1038/s41746-020-00323-1.
[37] Siontis KC, Noseworthy PA, Attia ZI, Friedman PA. Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nat Rev Cardiol. 2021;18:465-478. doi:10.1038/s41569-020-00503-2.
[38] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9-21. doi:10.1056/NEJMoa2212948.
[39] Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512-527. doi:10.1001/jama.2023.13239.
[40] Falcone T, Flyckt R. Clinical management of endometriosis. Obstet Gynecol. 2018;131:557-571. doi:10.1097/AOG.0000000000002469.
[41] Mackall CL, Bollard CM, Goodman N, et al. Enhancing pediatric access to cell and gene therapies. Nat Med. 2024;30:1836-1846. doi:10.1038/s41591-024-03035-1.
[42] Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics. Genet Med. 2021;23:2029-2037. doi:10.1038/s41436-021-01242-6.
[43] Fu X, She Y, Jin G, et al. Comparison of robotic-assisted total knee arthroplasty: an updated systematic review and meta-analysis. J Robot Surg. 2024;18:292. doi:10.1007/s11701-024-02045-y.
[44] Alrajeb R, Zarti M, Shuia Z, et al. Robotic-assisted versus conventional total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. Eur J Orthop Surg Traumatol. 2024;34:1333-1343. doi:10.1007/s00590-023-03798-2.
[45] Wu Z, Zheng Y, Zhang X. Safety and efficacy of orthopedic robots in total hip arthroplasty: a network meta-analysis and systematic review. J Orthop Surg Res. 2024;19(1):846. doi:10.1186/s13018-024-05279-6.
[46] Piliuk K, Tomforde S. Artificial intelligence in emergency medicine: a systematic literature review. Int J Med Inform. 2023;180:105274. doi:10.1016/j.ijmedinf.2023.105274.
[47] Almulihi QA, Alquraini AA, Almulihi FAA, et al. Applications of artificial intelligence and machine learning in emergency medicine triage: a systematic review. Med Arch. 2024;78:198-206. doi:10.5455/medarh.2024.78.198-206.
[48] McGenity C, Clarke EL, Jennings C, et al. Artificial intelligence in digital pathology: a systematic review and meta-analysis of diagnostic test accuracy. NPJ Digit Med. 2024;7:114. doi:10.1038/s41746-024-01106-8.
[49] Matthews GA, McGenity C, Bansal D, et al. Public evidence on AI products for digital pathology. NPJ Digit Med. 2024;7:300. doi:10.1038/s41746-024-01294-3.
[50] Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. doi:10.1136/bmj-2023-078378.
[51] Lekadir K, Frangi AF, Porras AR, et al.; FUTURE-AI Consortium. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ. 2025;388:e081554. doi:10.1136/bmj-2024-081554.
[52] Gallifant J, Afshar M, Ameen S, et al. The TRIPOD-LLM reporting guideline for studies using large language models. Nat Med. 2025;31:60-69. doi:10.1038/s41591-024-03425-5.
[53] Tsuchikama K, Anami Y, Ha SYY, et al. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203-223. doi:10.1038/s41571-023-00850-2.
[54] Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47-66. doi:10.1038/s41571-023-00832-4.
[55] Pantel K, Alix-Panabières C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol. 2025;22:65-77. doi:10.1038/s41571-024-00967-y.
[56] Chae A, Yao MS, Sagreiya H, et al. Strategies for implementing machine learning algorithms in the clinical practice of radiology. Radiology. 2024;310(1):e223170. doi:10.1148/radiol.223170.
[57] Minichmayr IK, Dreesen E, Centanni M, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215:115421. doi:10.1016/j.addr.2024.115421.
[58] Gant Kanegusuku AL, Chan CW, O'Donnell PH, Yeo KTJ. Implementation of pharmacogenomics testing for precision medicine. Crit Rev Clin Lab Sci. 2024;61(2):89-106. doi:10.1080/10408363.2023.2255279.

[59] Phi NTT, Montori VM, Kunneman M, Ravaud P, Tran VT. Cumulative burden of digital health technologies for patients with multimorbidity: a systematic review. JAMA Netw Open. 2025;8(4):e257288. doi:10.1001/jamanetworkopen.2025.7288.

[60] Dibbets AC, Koldeweij C, Osinga EP, Scheepers HCJ, de Wildt SN. Barriers and facilitators for bringing model-informed precision dosing to the patient's bedside: a systematic review. Clin Pharmacol Ther. 2025;117(3):633-645. doi:10.1002/cpt.3510.

[61] Lee AY, Friedewald SM. Clinical implementation of AI in screening mammography: the essential role of prospective evaluation. Radiology. 2024;311(3):e241124. doi:10.1148/radiol.241124.

[62] Rilkoff H, Struck S, Ziegler C, Faye L, Paquette D, Buckeridge D. Innovations in public health surveillance: an overview of novel use of data and analytic methods. Can Commun Dis Rep. 2024;50(3-4):93-101. doi:10.14745/ccdr.v50i34a02.